Mivobulin Isethionate

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMivobulin Isethionate
Drug Alias Namemivobulina米伏布林羟乙基磺酸mivobulinum米沃布林羟乙基磺酸mivobuline +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsProstatic NeoplasmsSmall Cell Lung CarcinomaOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsSmall Cell Lung CarcinomaOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG